Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units - Tabular View

Tracking Information

First Received Date ^ICMJE

September 11, 2005

Last Updated Date

March 14, 2007

Start Date ^ICMJE

February 2005

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00167999 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Official Title ^ICMJE

Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.

Brief Summary

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Detailed Description

Study Phase

Phase IV

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Natural History, Longitudinal, Case Control, Prospective Study

Condition ^ICMJE

Gram-Positive Bacterial Infections
Escherichia Coli Infections
Klebsiella Infections

Intervention ^ICMJE

Drug: piperacillin-tazobactam

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

200

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Eligible patients of either sex, 15 years of age or older
Patients who are admitted to the department of hematology and oncology
Provide written informed consent

Exclusion Criteria:

Patients who have hypersensitivity to β-lactam antibiotics
Female who are pregnant or breast-feeding
Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Gender

Both

Ages

15 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Korea, Republic of

Administrative Information

NCT ID ^ICMJE

NCT00167999

Responsible Party

Study ID Numbers ^ICMJE

0910X-101676

Study Sponsor ^ICMJE

Wyeth

Collaborators ^ICMJE

Investigators ^ICMJE

Study Director:

Medical Monitor

Wyeth

Information Provided By

Wyeth

Verification Date

March 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP